

Introducing the All-New Geistlich Bio-Gide® Forte

Geistlich Bio-Gide® Forte is a new membrane based on proven collagen technology. It offers greater strength, easy to handle, and adapts to the ridge contour.

PRINCETON, NJ, UNITED STATES,
December 10, 2025 /
EINPresswire.com/ -- Geistlich is
presenting Geistlich Bio-Gide® Forte, a
new membrane based on proven
collagen technology. It offers greater
strength, is easy to handle, and adapts
to the ridge contour. The resorbable
membrane will be unveiled at the



annual meeting of the American Academy of Periodontology (AAP).

Geistlich continuously expands its product portfolio to provide clinicians and patients worldwide with even more regenerative solutions. The family-owned company is launching Geistlich Bio-Gide® Forte, an advanced collagen membrane that supports reliable bone regeneration and optimal tissue integration. With its differentiated handling properties and high tensile strength, Geistlich Bio-Gide® Forte is designed for use in a wide range of bone and soft tissue regeneration cases.1,2

Proven Geistlich Bio-Gide® technology with added strength

Mark Spilker, Chief Science Officer at Geistlich, says: "With Geistlich Bio-Gide® Forte, we are expanding our membrane portfolio by offering a version of Geistlich Bio-Gide® that delivers particularly robust handling." Geistlich Bio-Gide® Forte is particularly firm and stable when hydrated. The membrane unfolds easily, can be cut even when hydrated, and enables tailoring to the size and shape of defects, providing precise adaptation and optimal coverage.1 Building on the excellent properties of Geistlich Bio-Gide® technology, the new product also helps to improve the survival rate of implants.3

References:

- 1. Data on File, Usability Test 2025, Geistlich Pharma AG, Wolhusen, Switzerland.
- 2. Dewilde F, Hindryckx M, Younes F, Bruyckere TD, Cosyn J. Clin. Implant Dent. Relat. Res. 2024.doi:10.1111/cid.13313 Epub ahead of print.
- 3. Knofler W, Barth T, Graul R, Krampe D. International journal of implant dentistry 2016.;2:25.

Jamie Bratton
Geistlich Pharma North America
+1 855-799-5500
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/873968259

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.